Circassia Completes Patient Recruitment For Phase II Clinical Trial Of Toleromune(R) Allergy Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy and critical care, announced that following successful clinical results achieved in 2008 with its ToleroMune(R) anti-allergy technology, the company has now completed patient recruitment for a further phase II clinical trial in cat allergy.

More: continued here

Filed under: Allergies on January 11th, 2009